Katalin Karikó has started a new research project

Katalin Karikó, the Nobel laureate biochemist, has initiated a new research project focused on treating hereditary diseases alongside her daughter. They aim to develop a therapeutic procedure targeting conditions caused by abnormal repetitions of base triplets or hexamers, such as Huntington's disease, ALS, and frontotemporal dementia. Their oral medication is currently undergoing clinical trials in Australia, and they have received approval to test its efficacy on ALS patients. Additionally, Karikó is involved in a program at the University of Szeged to develop mRNA-based therapies for fungal infection-related inflammatory diseases. The mRNA technology is being utilized in various innovative treatments globally, including a skin cancer vaccine by Moderna that has recently completed phase three clinical trials and may be available in the U.S. next year.